Your browser doesn't support javascript.
loading
Intraoperative radiation therapy as part of planned monotherapy for early-stage breast cancer.
Chowdhry, Varun K; Bushey, Julie A; Kwait, Rebecca M; Goldberg, Saveli; Ritchie, Jeannine; Ji, Yong-Li; McKee, Roderick; Palladino, Diane; Proulx, Gary M.
Afiliação
  • Chowdhry VK; 1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA USA.
  • Bushey JA; 2Department of Radiation Oncology, Exeter Hospital, Exeter, NH, USA.
  • Kwait RM; 3Core Physicians, Department of Surgery, Exeter Hospital, Exeter, NH, USA.
  • Goldberg S; 1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA USA.
  • Ritchie J; 4Department of Pathology, Exeter Hospital, Exeter, NH, USA.
  • Ji YL; 5Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA USA.
  • McKee R; 3Core Physicians, Department of Surgery, Exeter Hospital, Exeter, NH, USA.
  • Palladino D; 3Core Physicians, Department of Surgery, Exeter Hospital, Exeter, NH, USA.
  • Proulx GM; 1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA USA.
J Radiat Oncol ; 7(2): 167-173, 2018.
Article em En | MEDLINE | ID: mdl-29937985
ABSTRACT

INTRODUCTION:

Adjuvant whole breast radiation therapy has developed into the standard of care for patients following a lumpectomy for early-stage breast cancer. However, there is recent interest in intraoperative radiation therapy (IORT) to minimize toxicity while still improving local control beyond surgical resection and anti-estrogen therapy alone. MATERIALS AND

METHODS:

All patients were evaluated pre-operatively in a multidisciplinary clinic setting at a community hospital for suitability for breast conservation therapy. A total of 109 patients were reviewed receiving 110 IORT treatments. Patients were followed with clinical breast examinations and mammography as clinically indicated.

RESULTS:

At a median follow-up of 29.9 months, 2/110 (1.8%) patients experienced a local failure. One patient (0.9%) experienced a regional failure. Local control, disease-free survival and overall survival at 3 years were 98.9% (95%CI 92.2-99.8), 97.2% (95%CI 88.9-99.3), and 96.0% (95%CI 84.9-99.0), respectively. Five-year local control, disease-free survival, and overall survival rates were 96.3% (95%CI 84.7-99.2), 94.6% (95%CI 83.2-98.3), and 92.5% (95%CI 80.4-97.3), respectively. Patient self-reported cosmetic outcome was available for 51 patients, with all patients reporting being either very pleased, pleased, or satisfied with their cosmetic outcome, and no patients reported being dissatisfied or worse.

CONCLUSIONS:

The results of our series suggest the feasibility of utilizing IORT in a community-based cancer center with a high degree of local control, and patient satisfaction with regard to cosmesis. While the results of this series suggest that IORT may be a promising modality, longer follow-up is warranted to better understand exactly which clinicopathological features can predict long-term locoregional disease control.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article